Bill > HR3493

This bill aims to reduce prescription drug prices in the United States by implementing several key strategies. The bill would require the Secretary of Health and Human Services to propose rules establishing "most-favored-nation price targets" that would align U.S. pharmaceutical prices with those in other developed countries, ensuring comparable pricing. It also mandates the Secretary to certify that drug importation from other countries can be done safely and would significantly reduce prescription drug costs for American patients, with provisions for individuals to potentially import drugs on a case-by-case basis. The bill calls for the Attorney General and Federal Trade Commission to take enforcement actions against anticompetitive practices by pharmaceutical manufacturers, and directs the Secretary of Health and Human Services to facilitate direct-to-consumer purchasing programs at the new, lower prices. Additionally, the bill requires the Secretary of Commerce and the U.S. Trade Representative to conduct a study examining whether pharmaceutical manufacturers' practices are unreasonable or discriminatory, potentially harming national security, forcing U.S. patients to subsidize global research and development, or suppressing drug prices in foreign markets. The study's findings would be reported to Congress within 180 days of the bill's enactment.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/3493/all-info